Market Cap 563.07M
Revenue (ttm) 106.47M
Net Income (ttm) 83.23M
EPS (ttm) N/A
PE Ratio 9.86
Forward PE 22.36
Profit Margin 78.17%
Debt to Equity Ratio 0.00
Volume 6,941,200
Avg Vol 1,875,206
Day's Range N/A - N/A
Shares Out 59.12M
Stochastic %K 10%
Beta 0.85
Analysts Strong Sell
Price Target $28.25

Company Profile

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational p...

Industry: Biotechnology
Sector: Healthcare
Phone: 888 958 1253
Address:
101 Federal Street, Suite 103, Boston, United States
TNNStockAnalysisNews
TNNStockAnalysisNews Jul. 27 at 1:21 AM
Stocks Under $10 To Watch Tomorrow (July 27, 2026): $OPEN $BBAI $ZVRA $FRMI $DJT https://truthsandnews.com/markets/top-10-stocks-under-10-to-watch-tomorrow-july-27-lucid-nio-fermi
0 · Reply
RaySan
RaySan Jul. 27 at 12:45 AM
$ZVRA Someone mentioned that Neil has been at the helm of a company or 2 that were bought out. Is this true and if so what are our chances of a BO and how soon?
1 · Reply
Biotechnicity
Biotechnicity Jul. 26 at 11:07 PM
$ZVRA After FDA felt political pressure leading to Sarepta’s eteplirsen approval in which the sponsor refused to conduct a legit trial — and while in the midst of helping Orphazyme cobble together a stat-sig Phase 2/3 arimoclomol study by identifying 2-patients unresponsive to therapy and wondering where missing data from 4-patients was (SAE’s provoking the disappearance?) — they were working with $CYTH (now $RFL) on designing a study that would prove whether or not Trappsol-Cyclo was a safe & effective therapy for NPC patients. It is almost twice as large (104-patients). It is robust with well designed endpoints. And, given the problematic history of eteplirsen and arimoclomol, was unpartnered. No one believed such a study could readout stat-sig. I still don’t. But neither did FDA which simply asked for a study that could adequately demonstrate a relationship between therapy and the targeted outcome. Completely unfair to the new sponsor, Raphael! But a study embraced by FDA & EMA.
3 · Reply
intowits
intowits Jul. 26 at 10:40 PM
$ZVRA Zevra's NDA was for adults & children 2 yrs & up. But their MAA is for adults & children 6 mos & up. This how Aqneursa got approved, quoted from their CHMP ASSESSMENT REPORT: "The initially claimed indication for Aqneursa (their original MAA filing) was the following:" “Aqneursa is indicated in adults and CHILDREN FROM BIRTH for chronic treatment of Niemann-Pick Type C.” "Following comments and RECOMMENDATIONS FROM THE CHMP, the Applicant agreed to the final indication below:" “Aqneursa is indicated for the treatment of neurological manifestations of Niemann-Pick type C disease, in combination with miglustat, or as a monotherapy in patients where miglustat is not tolerated, in adults and children AGED 6 YEARS AND OLDER AND WEIGHING AT LEAST 20 kg.” PAGE 107 of the CHMPs Aqneursa Assessment Report: https://www.ema.europa.eu/en/documents/assessment-report/aqneursa-epar-public-assessment-report_en.pdf
0 · Reply
intowits
intowits Jul. 26 at 7:52 PM
$ZVRA per AI: (page 1 of 2-3) Historically, approx 25% to 35% of re-exams for MAAs successfully reverse an initial neg opinion. While it is possible, the majority (65% to 75%) of initial neg opinions issued by the CHMP are upheld or result in the applicant withdrawing the drug entirely before a final vote. Stats of Re-Exams Because the EMA evaluates applications on strict scientific criteria, changing the CHMPs mind w/o submitting entirely NEW TRIALS is highly challenging. Analyses of recent periods highlight how these play out: The 2021–2025 Cohort: A recent study tracked 16 MAAs that received a formal neg opinion. Out of those, 12 apps filed for a re-examination. The outcomes were: 58.3% (7 apps) received a 2nd, final neg opinion. 41.7% (5 apps) were withdrawn by the co mid-procedure after realizing the neg opinion would not be overturned. 0% were reversed in this specific 5 yr data slice
2 · Reply
Market_Pulse_Report
Market_Pulse_Report Jul. 26 at 6:00 PM
0 · Reply
CMAJR69
CMAJR69 Jul. 26 at 3:19 PM
$ZVRA I’m nothing if not consistent…. FUCK YOU NEIL‼️
0 · Reply
ReggieWhit2
ReggieWhit2 Jul. 25 at 11:32 PM
$ZVRA I know this is way too simplistic and not accounting for all the variables and personalities involved, but the Board ought to just tell Neil the Eel to bring Travis onboard, at $2 million plus options and maybe a Board seat if necessary, and give him free reign to run the show to bring this across the goal line. It's quite obvious that the overpaid C-suite Phd's and MD's are not up to the task. How many VP's of Whatever do we have? And, who in the hell prepared and made the presentation? Neil would be looked upon as a selfless, and forward thinking CEO by doing this. But I'm afraid he's not able to suck it up for the betterment of the company or long term shareholders, who have supported the value of the company over the years, by this directive.
3 · Reply
WaynD01
WaynD01 Jul. 25 at 10:34 PM
$ZVRA And it happened so!! Is there a Time machine available for me to change my proxy vote to oust to Pascoe ? I have been asking thid for some time..
0 · Reply
intowits
intowits Jul. 25 at 9:45 PM
$ZVRA per AI: There is no official, running total of every drug historically approved by the FDA, not by the EMA. However, extensive regulatory tracking studies show that the 2 agencies agree on more than 90% of drug approval decisions, making final outright rejections relatively rare. Historical cohort studies track how often the agencies reach completely opposite final conclusions on the exact same data package: The 2014–2016 Cohort: Out of 107 joint drug applications studied by both agencies, the EMA and FDA had final discordant marketing decisions for only two drugs: corifollitropin alfa and ataluren. The 2017–2020 Cohort: A follow-up study analyzing 206 new drugs approved by the FDA found that only 5 drugs were explicitly refused marketing authorization by an international regulatory body like the EMA due to unfavorable benefit-to-risk assessment.
0 · Reply
Latest News on ZVRA
Zevra Therapeutics chief medical officer to step down

2026-06-11T13:15:49.000Z - 6 weeks ago

Zevra Therapeutics chief medical officer to step down


Zevra Therapeutics Slides: Corporate presentation

Jun 2, 2026, 7:00 AM EDT - 7 weeks ago

Zevra Therapeutics Slides: Corporate presentation


Zevra Therapeutics reports Q1 EPS 60c, consensus 8c

2026-05-07T00:44:27.000Z - 2 months ago

Zevra Therapeutics reports Q1 EPS 60c, consensus 8c


Zevra Therapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Zevra Therapeutics Earnings Call Transcript: Q1 2026


Zevra Therapeutics Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Zevra Therapeutics Earnings release: Q1 2026


Zevra Therapeutics Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Zevra Therapeutics Quarterly report: Q1 2026


Zevra Therapeutics Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 3 months ago

Zevra Therapeutics Proxy statement: Proxy filing


Zevra Therapeutics Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 3 months ago

Zevra Therapeutics Proxy statement: Proxy filing


Zevra Therapeutics Slides: Corporate presentation

Apr 6, 2026, 7:00 AM EDT - 3 months ago

Zevra Therapeutics Slides: Corporate presentation


Zevra Therapeutics sells SDX portfolio to Commave for $50M

2026-03-16T11:35:43.000Z - 4 months ago

Zevra Therapeutics sells SDX portfolio to Commave for $50M


Zevra Therapeutics initiated with a Buy at BTIG

2026-03-16T10:41:37.000Z - 4 months ago

Zevra Therapeutics initiated with a Buy at BTIG


Zevra Therapeutics Earnings Call Transcript: Q4 2025

Mar 9, 2026, 4:30 PM EDT - 4 months ago

Zevra Therapeutics Earnings Call Transcript: Q4 2025


Zevra Therapeutics Annual report: Q4 2025

Mar 9, 2026, 4:30 PM EDT - 4 months ago

Zevra Therapeutics Annual report: Q4 2025


Zevra Therapeutics Earnings release: Q4 2025

Mar 9, 2026, 4:30 PM EDT - 4 months ago

Zevra Therapeutics Earnings release: Q4 2025


Zevra Therapeutics Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 4 months ago

Zevra Therapeutics Slides: Corporate presentation


Zevra Therapeutics, Inc. Announces CFO Transition

Nov 20, 2025, 4:05 PM EST - 8 months ago

Zevra Therapeutics, Inc. Announces CFO Transition


Zevra Therapeutics Earnings Call Transcript: Q3 2025

Nov 5, 2025, 4:30 PM EST - 9 months ago

Zevra Therapeutics Earnings Call Transcript: Q3 2025


Zevra Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 4:30 PM EST - 9 months ago

Zevra Therapeutics Quarterly report: Q3 2025


Zevra Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 4:30 PM EST - 9 months ago

Zevra Therapeutics Earnings release: Q3 2025


Zevra Therapeutics Slides: Corporate Presentation

Nov 4, 2025, 6:00 PM EST - 9 months ago

Zevra Therapeutics Slides: Corporate Presentation


Zevra Therapeutics Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Earnings Call Transcript: Q2 2025


Zevra Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Quarterly report: Q2 2025


Zevra Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Earnings release: Q2 2025


Zevra Therapeutics Slides: Corporate Presentation

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Zevra Therapeutics Slides: Corporate Presentation


Zevra Therapeutics Slides: Corporate Presentation

Jun 2, 2025, 7:00 AM EDT - 1 year ago

Zevra Therapeutics Slides: Corporate Presentation


Zevra Therapeutics Proxy statement: Proxy Filing

May 21, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing


Zevra Therapeutics Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Earnings Call Transcript: Q1 2025


Zevra Therapeutics Quarterly report: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Quarterly report: Q1 2025


Zevra Therapeutics Earnings release: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Earnings release: Q1 2025


Zevra Therapeutics Proxy statement: Proxy Filing

May 8, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing


Zevra Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing


Zevra Therapeutics Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing


Zevra Therapeutics Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing


Zevra Therapeutics Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing


Zevra Therapeutics Proxy statement: Proxy Filing

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing


Zevra Therapeutics Proxy statement: Proxy Filing

Apr 7, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing


Zevra Therapeutics Files Preliminary Proxy

Mar 31, 2025, 4:12 PM EDT - 1 year ago

Zevra Therapeutics Files Preliminary Proxy


Zevra Therapeutics Proxy statement: Proxy Filing

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing


Zevra Therapeutics Proxy statement: Proxy Filing

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing


Zevra Therapeutics Proxy statement: Proxy Filing

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing


Zevra Therapeutics Earnings Call Transcript: Q4 2024

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Earnings Call Transcript: Q4 2024


Zevra Therapeutics Annual report: Q4 2024

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Annual report: Q4 2024


Zevra Therapeutics Earnings release: Q4 2024

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Earnings release: Q4 2024


Zevra to Participate at Upcoming Investor Conferences

Feb 24, 2025, 4:02 PM EST - 1 year ago

Zevra to Participate at Upcoming Investor Conferences


Zevra Therapeutics Announces Organizational Changes

Dec 6, 2024, 5:00 PM EST - 1 year ago

Zevra Therapeutics Announces Organizational Changes


Zevra Therapeutics Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Zevra Therapeutics Earnings Call Transcript: Q3 2024


Zevra Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Zevra Therapeutics Quarterly report: Q3 2024


Zevra Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Zevra Therapeutics Earnings release: Q3 2024


Zevra Therapeutics Slides: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Zevra Therapeutics Slides: Q3 2024


TNNStockAnalysisNews
TNNStockAnalysisNews Jul. 27 at 1:21 AM
Stocks Under $10 To Watch Tomorrow (July 27, 2026): $OPEN $BBAI $ZVRA $FRMI $DJT https://truthsandnews.com/markets/top-10-stocks-under-10-to-watch-tomorrow-july-27-lucid-nio-fermi
0 · Reply
RaySan
RaySan Jul. 27 at 12:45 AM
$ZVRA Someone mentioned that Neil has been at the helm of a company or 2 that were bought out. Is this true and if so what are our chances of a BO and how soon?
1 · Reply
Biotechnicity
Biotechnicity Jul. 26 at 11:07 PM
$ZVRA After FDA felt political pressure leading to Sarepta’s eteplirsen approval in which the sponsor refused to conduct a legit trial — and while in the midst of helping Orphazyme cobble together a stat-sig Phase 2/3 arimoclomol study by identifying 2-patients unresponsive to therapy and wondering where missing data from 4-patients was (SAE’s provoking the disappearance?) — they were working with $CYTH (now $RFL) on designing a study that would prove whether or not Trappsol-Cyclo was a safe & effective therapy for NPC patients. It is almost twice as large (104-patients). It is robust with well designed endpoints. And, given the problematic history of eteplirsen and arimoclomol, was unpartnered. No one believed such a study could readout stat-sig. I still don’t. But neither did FDA which simply asked for a study that could adequately demonstrate a relationship between therapy and the targeted outcome. Completely unfair to the new sponsor, Raphael! But a study embraced by FDA & EMA.
3 · Reply
intowits
intowits Jul. 26 at 10:40 PM
$ZVRA Zevra's NDA was for adults & children 2 yrs & up. But their MAA is for adults & children 6 mos & up. This how Aqneursa got approved, quoted from their CHMP ASSESSMENT REPORT: "The initially claimed indication for Aqneursa (their original MAA filing) was the following:" “Aqneursa is indicated in adults and CHILDREN FROM BIRTH for chronic treatment of Niemann-Pick Type C.” "Following comments and RECOMMENDATIONS FROM THE CHMP, the Applicant agreed to the final indication below:" “Aqneursa is indicated for the treatment of neurological manifestations of Niemann-Pick type C disease, in combination with miglustat, or as a monotherapy in patients where miglustat is not tolerated, in adults and children AGED 6 YEARS AND OLDER AND WEIGHING AT LEAST 20 kg.” PAGE 107 of the CHMPs Aqneursa Assessment Report: https://www.ema.europa.eu/en/documents/assessment-report/aqneursa-epar-public-assessment-report_en.pdf
0 · Reply
intowits
intowits Jul. 26 at 7:52 PM
$ZVRA per AI: (page 1 of 2-3) Historically, approx 25% to 35% of re-exams for MAAs successfully reverse an initial neg opinion. While it is possible, the majority (65% to 75%) of initial neg opinions issued by the CHMP are upheld or result in the applicant withdrawing the drug entirely before a final vote. Stats of Re-Exams Because the EMA evaluates applications on strict scientific criteria, changing the CHMPs mind w/o submitting entirely NEW TRIALS is highly challenging. Analyses of recent periods highlight how these play out: The 2021–2025 Cohort: A recent study tracked 16 MAAs that received a formal neg opinion. Out of those, 12 apps filed for a re-examination. The outcomes were: 58.3% (7 apps) received a 2nd, final neg opinion. 41.7% (5 apps) were withdrawn by the co mid-procedure after realizing the neg opinion would not be overturned. 0% were reversed in this specific 5 yr data slice
2 · Reply
Market_Pulse_Report
Market_Pulse_Report Jul. 26 at 6:00 PM
0 · Reply
CMAJR69
CMAJR69 Jul. 26 at 3:19 PM
$ZVRA I’m nothing if not consistent…. FUCK YOU NEIL‼️
0 · Reply
ReggieWhit2
ReggieWhit2 Jul. 25 at 11:32 PM
$ZVRA I know this is way too simplistic and not accounting for all the variables and personalities involved, but the Board ought to just tell Neil the Eel to bring Travis onboard, at $2 million plus options and maybe a Board seat if necessary, and give him free reign to run the show to bring this across the goal line. It's quite obvious that the overpaid C-suite Phd's and MD's are not up to the task. How many VP's of Whatever do we have? And, who in the hell prepared and made the presentation? Neil would be looked upon as a selfless, and forward thinking CEO by doing this. But I'm afraid he's not able to suck it up for the betterment of the company or long term shareholders, who have supported the value of the company over the years, by this directive.
3 · Reply
WaynD01
WaynD01 Jul. 25 at 10:34 PM
$ZVRA And it happened so!! Is there a Time machine available for me to change my proxy vote to oust to Pascoe ? I have been asking thid for some time..
0 · Reply
intowits
intowits Jul. 25 at 9:45 PM
$ZVRA per AI: There is no official, running total of every drug historically approved by the FDA, not by the EMA. However, extensive regulatory tracking studies show that the 2 agencies agree on more than 90% of drug approval decisions, making final outright rejections relatively rare. Historical cohort studies track how often the agencies reach completely opposite final conclusions on the exact same data package: The 2014–2016 Cohort: Out of 107 joint drug applications studied by both agencies, the EMA and FDA had final discordant marketing decisions for only two drugs: corifollitropin alfa and ataluren. The 2017–2020 Cohort: A follow-up study analyzing 206 new drugs approved by the FDA found that only 5 drugs were explicitly refused marketing authorization by an international regulatory body like the EMA due to unfavorable benefit-to-risk assessment.
0 · Reply
intowits
intowits Jul. 25 at 9:27 PM
$ZVRA Roth MKM analyst Jonathan Aschoff maintained a Buy rating on Zevra Therapeutics today and set a price target of $21.00. The company’s shares closed last Friday at $9.50, close to its 52-week high of $9.76. In a report released yesterday, TipRanks – PerPlexity also reiterated a Buy rating on the stock with a $14.00 price target.
0 · Reply
Kittinvestments
Kittinvestments Jul. 25 at 8:30 PM
$ZVRA one thing to keep in mind with the CHMP decision not to approve Mypliffa is that it is just an opinion. The European Commission is the one that decides and could also overrule the opinion of the CHMP. So after the re-examination, the EC could still approve Mypliffa in 2027.
1 · Reply
intowits
intowits Jul. 25 at 8:03 PM
$ZVRA How ironic: "The company also noted that updated international clinical management guidelines include arimoclomol as a treatment option for patients with NPC."
2 · Reply
intowits
intowits Jul. 25 at 7:56 PM
$ZVRA "Zevra Therapeutics Institutional Equity Analysis and Valuation Report https://youtu.be/fwdJ__QAQ4w?si=LzCId4JV5lKbFetV
0 · Reply
Wahoos
Wahoos Jul. 25 at 7:47 PM
$ZVRA As I stated previously, the only black swan is if Aqneursa poaches our patients or someone invents a better mousetrap.
0 · Reply
intowits
intowits Jul. 25 at 7:42 PM
$ZVRA CHMP said "no benefit was seen in ambulation & cognition" (using the 5-domain criteria). During Miplyffa's NDA processing the clinical criteria changed from a 5-domain scale to a 4-domain because FDA challenged the statistical validity, reliability, & "interpretability" of the original 5-domain. Z initially submitted the NDA, they measured NPC progression using the 5-Domain NPC Scale. The scale was updated to the Rescored 4-Domain scale due to 2 primary issues raised by the FDA: 1. Removal of the Cognition Domain FDA noted that ratings within the original cognition domain relied heavily on patient environment factors & external access to services (such as specialized schooling or therapeutic infrastructure). Because these external factors varied wildly by patient & location, FDA concluded that the cognition domain could not be accurately or objectively evaluated by a clinical severity scale to prove drug efficacy. Cont'd
1 · Reply
ZVRA100
ZVRA100 Jul. 25 at 6:56 PM
$ZVRA i mean, the existing revenue structure already gets close to $0.20 EPS per quarter with just US miplyffa and EAP. With no growth and 20 PER, that’s still a $16 for the next decade or so. And US millyffa will continue to grow, so this is an overreaction. Buying more.
0 · Reply
ProphetofProfits20
ProphetofProfits20 Jul. 25 at 5:25 PM
$ZVRA OK, read the whole report from the EMA. Here is what stood out to me about the refusal. "What were the main reasons for refusing the marketing authorisation? Based on the submitted data, the Agency concluded that the efficacy of Meplyffa had not been sufficiently demonstrated. Due to the way the data had been handled and the results analysed, there were uncertainties about the reliability and robustness of the results. Moreover, no benefit was seen in terms of ambulation and cognition. " If I'm reading this correctly, the EMA seems to be looking for a reason for refusal. Due to the way data had been handled and the results anaylsed is vague. Without specifics on the details, they can say that about almost anything. The EMA chose to cast doubt on the "robustness of the results" because of their vague reasoning. The science behind the study does show results. Now, the appeal could boil down to choosing to believe the study or not. A different review panel may see it differently.
3 · Reply
HuntingHighAndLow
HuntingHighAndLow Jul. 25 at 2:27 PM
$ZVRA Please excuse any redundancy in linking this summary material on the CHMP opinion. Any guesses as to why Miplyffa is referred to as "Meplyffa"? I would guess that stems from Zevra. https://www.ema.europa.eu/en/medicines/human/EPAR/meplyffa
1 · Reply
Market_Pulse_Report
Market_Pulse_Report Jul. 25 at 2:00 PM
$ZVRA Institutional Equity Analysis and Valuation Report. Check out this great informative video! https://youtu.be/fwdJ__QAQ4w?si=gEMWcz7TmEiYQJ58
1 · Reply
Wahoos
Wahoos Jul. 25 at 1:59 PM
$ZVRA Surprisingly, the short volume yesterday was only 1.6 million shares or 48%.
0 · Reply
lance1965
lance1965 Jul. 25 at 1:15 PM
$ZVRA Today's words are " BAKED IN"
0 · Reply